bought $ BLUE in $80's sold at $150, made a killing this looks better
thats all folks
Briefing In Play
ZYNE is a specialty pharmaceutical co focused on developing and commercializing proprietary next-genertion synthetic cannabinoid therapeutics formulated for transdermal delivery.Investors are likely to see this as a buy opportunity, GW Pharma's (GWPH) performance is up over ~1000% since listing in the US.
crushes last 4 qts
what a joke